ACE2 and breast cancer: The higher expression of ACE2 was correlated with a better prognosis in luminal B-type breast cancer (RFS: HR 0.76, 95% CI = 0.63-0.92, p = 0.005; DMFS: HR 0.70, 95% CI = 0.49-1.00, p = 0.046).